中国梦：没有乙型肝炎的未来.

In China, hepatitis B virus (HBV) infection remains a great threat to public health. Preventing the mother-to-child transmission (MTCT) of HBV is the main method to reduce the harm and disease burden caused by viral hepatitis in China. Recent studies have demonstrated that antiviral therapy with tenofovir disoproxil fumarate (TDF) during late pregnancy for mothers can further reduce MTCT of HBV. Meanwhile, Chinese Foundation for Hepatitis Prevention and Control launched the Hepatitis B Shield Project on July 25, 2015. This project aims to further reduce or even eliminate MTCT of HBV by means of standard management of pregnant women with HBV via a mobile-health application. At present, China has made great achievements in fighting against HBV. We believe that the remarkable findings of such studies and the launch of the Chinese Shield Project will make the Chinese dream-HBV-free generation come true in the near future. [ABSTRACT FROM AUTHOR]